Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
resminostat + FOLFIRI
- Development stage
- Unknown
- Lead developer
- 4SC
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Resminostat + FOLFIRI is an investigational drug combination studied primarily in the context of advanced or metastatic colorectal cancer, especially in patients with KRAS mutations. **Resminostat** is an orally available pan-histone deacetylase (HDAC) inhibitor, which disrupts tumor cell DNA structure, promoting differentiation and apoptosis. **FOLFIRI** is a widely used intravenous chemotherapy regimen containing folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. FOLFIRI works by interfering with DNA synthesis and replication, targeting rapidly dividing cancer cells. The combination is designed to enhance antitumor activity and provide a potential new therapeutic option for patients who have failed other regimens.
- Other names
- FOLFIRI
02
Targets
TOP1 (DNA Topoisomerase I)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)HDAC8 (Histone Deacetylase 8)TS (Thymidylate synthase)
Beyond the preview
Go deeper on resminostat + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on resminostat + FOLFIRI.